The disconnect between preclinical animal data and human trial outcomes remains a critical bottleneck in drug development. While rodent models have long been the industry standard, their inability to replicate human muscle physiology—such as metabolic responses, neuromuscular interactions, or disease-specific pathology—contributes to a 95% clinical attrition rate for musculoskeletal therapies. Myomaker Bio addresses this challenge with TRL 9-validated 3D
Read More

Over 300 million people worldwide suffer from rare diseases, many with no treatments. Traditional drug discovery ignores these conditions—too niche, too risky. But what if you could test therapies on human muscle engineered to mirror exact disease biology? Myomaker Bio’s platform does just that. We recently partnered with a biotech to screen 1,200 FDA-approved drugs for ALS using our neuromuscular junction
Read More

The disconnect between preclinical animal data and human trial outcomes remains a critical bottleneck in drug development. While rodent models have long been the industry standard, their inability to replicate human muscle physiology—such as metabolic responses, neuromuscular interactions, or disease-specific pathology—contributes to a 95% clinical attrition rate for musculoskeletal therapies. Myomaker Bio addresses this challenge with TRL 9-validated 3D
Read More

Over 300 million people worldwide suffer from rare diseases, many with no treatments. Traditional drug discovery ignores these conditions—too niche, too risky. But what if you could test therapies on human muscle engineered to mirror exact disease biology? Myomaker Bio’s platform does just that. We recently partnered with a biotech to screen 1,200 FDA-approved drugs for ALS using our neuromuscular junction
Read More